Stereotactic Body Radiation Therapy for Spinal Malignancies
Open Access
- 1 January 2018
- journal article
- review article
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 17, 1-15
Abstract
Stereotactic body radiation therapy and stereotactic radiosurgery have become important treatment options for the treatment of spinal malignancies. A better understanding of dose tolerances with more conformal technology have allowed administration of higher and more ablative doses. In this review, the framework for approaching a patient with spinal metastases and primary tumors will be discussed as well as details on the delivery of this treatment.Keywords
This publication has 106 references indexed in Scilit:
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2013
- Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1–2 trialThe Lancet Oncology, 2012
- Immunologic Correlates of the Abscopal Effect in a Patient with MelanomaNew England Journal of Medicine, 2012
- Fiducial-free CyberKnife stereotactic body radiation therapy (SBRT) for single vertebral body metastases: acceptable local control and normal tissue tolerance with 5 fraction approachFrontiers in Oncology, 2012
- Stereotactic Body Radiotherapy Reirradiation for Recurrent Epidural Spinal MetastasesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Current state of knowledge regarding the use of antiangiogenic agents with radiation therapyCancer Treatment Reviews, 2011
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 AntibodyClinical Cancer Research, 2009
- Stereotactic Body Radiotherapy for Lesions of the Spine and Paraspinal RegionsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Local control by radiotherapy: is that all there is?Breast Cancer Research, 2008
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007